Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.63 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.63 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | TACR1 | P25103 | 2/20 | 0.60 |
| ▸ | CTSL | P07711 | 1/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.58 |
| ▸ | CTSS | P25774 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10722503 | 1.00 | GPR34 (0.63) | GPR34ITGB3ITGA2BALDH1A1TACR1 | |
| SCHEMBL2511842 | 1.00 | GPR34 (0.63) | GPR34ITGB3ITGA2BALDH1A1TACR1 | |
| SCHEMBL7291131 | 1.00 | GPR34 (0.63) | GPR34ITGB3ITGA2BALDH1A1TACR1 | |
| SCHEMBL10724240 | 0.95 | TACR1 (0.61) | GPR34ITGB3ITGA2BALDH1A1TACR1 | |
| SCHEMBL10724885 | 0.95 | TACR1 (0.61) | GPR34ITGB3ITGA2BALDH1A1TACR1 | |
| SCHEMBL10724242 | 0.95 | TACR1 (0.61) | GPR34ITGB3ITGA2BALDH1A1TACR1 | |
| SCHEMBL10724879 | 0.95 | TACR1 (0.61) | GPR34ITGB3ITGA2BALDH1A1TACR1 | |
| SCHEMBL5396021 | 0.93 | GPR34 (0.76) | GPR34ITGB3ITGA2B | |
| SCHEMBL5396470 | 0.93 | GPR34 (0.76) | GPR34ITGB3ITGA2B | |
| SCHEMBL219151 | 0.92 | TACR1 (0.68) | ITGB3ITGA2BALDH1A1TACR1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| US-20070185060-A1 | Boronic acid thrombin inhibitors | TRIGEN LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185060-A1 | Boronic acid thrombin inhibitors | TRIGEN LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20050282757-A1 | Peptide boronic acid compounds useful in anticoagulation | TRIGEN LIMITED | 2005-12-22 | — | — | US | disclosed |
| US-20050282757-A1 | Peptide boronic acid compounds useful in anticoagulation | TRIGEN LIMITED | 2005-12-22 | — | — | US | disclosed |
| WO-2005084687-A2 | BORONIC ACID THROMBIN INHIBITORS | TRIGEN LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282757-A1 | Peptide boronic acid compounds useful in anticoagulation | SERPINC1, HABP2, F11 | GPR34 2853/4885ITGB3 1478/4885ITGA2B 1324/4885 |
| US-20070185060-A1 | Boronic acid thrombin inhibitors | F2, ECE1, BCAT1 | GPR34 4282/4885ITGB3 1337/4885ITGA2B 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.